Moderna was in focus after updated cancer vaccine data, while Novavax drew attention following its Pfizer licensing deal.

Sweeping U.S. policy changes under Health Secretary Robert F. Kennedy Jr. are having a chilling effect on vaccine makers as ...

The unprecedented changes have led to diminished vaccine usage, and created a drag that will likely dent revenues.

Sweeping changes to U.S. vaccine policy under Health Secretary Robert F. Kennedy Jr. are creating uncertainty across the pharmaceutical sector, dampening investor confidence and raising concerns among ...